ES2152935T3 - Metodo para suprimir la coloracion de la albumina serica humana. - Google Patents

Metodo para suprimir la coloracion de la albumina serica humana.

Info

Publication number
ES2152935T3
ES2152935T3 ES93104123T ES93104123T ES2152935T3 ES 2152935 T3 ES2152935 T3 ES 2152935T3 ES 93104123 T ES93104123 T ES 93104123T ES 93104123 T ES93104123 T ES 93104123T ES 2152935 T3 ES2152935 T3 ES 2152935T3
Authority
ES
Spain
Prior art keywords
coloration
serica
albumine
delete
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93104123T
Other languages
English (en)
Other versions
ES2152935T5 (es
Inventor
Akinori Sumi
Wataru Ohtani
Naoto Furuhata
Kazuya Takeshima
Kaeko Kamide
Takao Ohmura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Yoshitomi Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14031724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2152935(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yoshitomi Pharmaceutical Industries Ltd filed Critical Yoshitomi Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2152935T3 publication Critical patent/ES2152935T3/es
Publication of ES2152935T5 publication Critical patent/ES2152935T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

Un método para suprimir la coloración de la albúmina sérica humana expresada mediante ingeniería genética, que comprende el cultivo y/o la purificación en presencia de un compuesto amínico seleccionado entre metilendiamina; propilendiamina; N,N-dialquil(C1-6)alquilendiaminas(C1-6); guanidinas seleccionadas entre guanidina, aminoguanidina y fenilguanidina; benzamidinas seleccionadas entre benzamidina y p-aminobenzamidina; y aminoácidos básicos seleccionados entre lisina y arginina, en una proporción de 0,1 a 1% peso/vol con respecto al medio o a la fracción líquida que contiene la albúmina sérica humana.
ES93104123T 1992-03-16 1993-03-13 Metodo para suprimir la coloracion de la albumina serica humana. Expired - Lifetime ES2152935T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4-91624 1992-03-16
JP4091624A JPH07102147B2 (ja) 1992-03-16 1992-03-16 ヒト血清アルブミンの着色抑制方法

Publications (2)

Publication Number Publication Date
ES2152935T3 true ES2152935T3 (es) 2001-02-16
ES2152935T5 ES2152935T5 (es) 2007-05-16

Family

ID=14031724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93104123T Expired - Lifetime ES2152935T5 (es) 1992-03-16 1993-03-13 Metodo para suprimir la coloracion de la albumina serica humana.

Country Status (9)

Country Link
US (1) US5369020A (es)
EP (1) EP0591605B2 (es)
JP (1) JPH07102147B2 (es)
KR (1) KR0168689B1 (es)
CA (1) CA2091636C (es)
DE (1) DE69329841T3 (es)
DK (1) DK0591605T3 (es)
ES (1) ES2152935T5 (es)
TW (1) TW255914B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
CA2136564C (en) * 1993-11-26 2008-04-08 Kaoru Kobayashi Process for producing human serum albumin
CA2138349A1 (en) * 1993-12-17 1995-06-18 Welfide Corporation Method for decoloring human serum albumin
JPH07308199A (ja) 1994-05-18 1995-11-28 Green Cross Corp:The ヒト血清アルブミンの製造方法
JPH0823995A (ja) * 1994-07-14 1996-01-30 Green Cross Corp:The 宿主細胞由来のプロテアーゼで低分子化され得る蛋白質の製造方法
CA2157219C (en) 1994-08-31 2010-10-05 Munehiro Noda Process for purifying recombinant human serum albumin
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
SI2970875T2 (sl) * 2013-03-15 2026-03-31 F. Hoffmann-La Roche Ag Sestavki celičnih kultur z antioksidanti in postopki za proizvodnjo polipeptidov
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
EP4267210A1 (en) 2020-12-28 2023-11-01 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054489A (en) * 1975-09-26 1977-10-18 Nelli Isaakovna Zhdanova Method of preparing l-glutamic acid and its sodium salt
US4165258A (en) * 1975-10-08 1979-08-21 University Of Pennsylvania Plasminogen activating enzyme-specific competitive inhibitor
SE405549B (sv) * 1975-10-09 1978-12-18 Pharmacia Fine Chemicals Ab Forfarande for isolering av albumin ur plasmaprodukter genom kromatografisk fraktionering
FR2594846B1 (fr) * 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
JPH03262487A (ja) * 1990-03-12 1991-11-22 Tonen Corp ヒト血清アルブミンの安定な製造方法
JP3230091B2 (ja) * 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same

Also Published As

Publication number Publication date
JPH07102147B2 (ja) 1995-11-08
DE69329841D1 (de) 2001-02-15
DK0591605T3 (da) 2001-01-29
CA2091636A1 (en) 1993-09-17
DE69329841T3 (de) 2007-06-21
ES2152935T5 (es) 2007-05-16
EP0591605B1 (en) 2001-01-10
US5369020A (en) 1994-11-29
TW255914B (es) 1995-09-01
EP0591605B2 (en) 2006-11-15
DE69329841T2 (de) 2001-05-31
CA2091636C (en) 2004-02-03
KR0168689B1 (ko) 1999-01-15
EP0591605A2 (en) 1994-04-13
JPH05260986A (ja) 1993-10-12
EP0591605A3 (es) 1994-04-20
KR930019817A (ko) 1993-10-19

Similar Documents

Publication Publication Date Title
ES2152935T3 (es) Metodo para suprimir la coloracion de la albumina serica humana.
ATE224726T1 (de) Flüssige interferon-beta-formulierungen
AR043826A1 (es) Formulaciones de proteinas y anticuerpos de alta concentracion
ATE94754T1 (de) Verfahren und zusammensetzung zur herstellung von liposomen.
ES2123910T3 (es) Composiciones que contienen sales anfoteras de alfa-hidroxiacidos y monocaprilato de glicerol.
ES2141229T3 (es) Productos farmaceuticos de proteinas y peptidos modificados.
SE9202668D0 (sv) Alkyl-biacylfosfinoxider
PT1118619E (pt) Metodo para identificar agentes activos contra o vhc utilizando as coordenadas estruturais da protease do virus da hepatite c
PT885881E (pt) Acidos sulfonilalcanoilamino hidroxietilamino sulfamicos uteis como inibidores de protease retroviral
DE60106469D1 (de) Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen
DE69123140D1 (de) Co-unabhängiges nährmedium zur haltung und vermehrung von zellen
RU94030485A (ru) Способ использования, хранения и транспортировки фермента металлопротеазы в стабилизированной форме и водная композиция фермента металлопротеазы
ATE535544T1 (de) Verfahren zur verhinderung von polymeren des humanen serumalbumins
DE3685673D1 (de) Verfahren zur aufbewahrung von saeure produzierenden bakterien und demgemaess hergestellte zusammensetzungen.
ATE20540T1 (de) Vollsynthetisches zellkulturmedium.
ATE227705T1 (de) Reagenz zur guanidinylierung
MX171922B (es) Aditivo para combustoleo
ES2174481T3 (es) Empleo de soluciones que contienen enzimas para la limpieza de tanques de fermentacion o de almacenamiento.
PT99578A (pt) Processo para a reactivacao de uma proteina desnaturada
ES2052493T3 (es) Utilizacion de inhibidores de girasa para la descontaminacion de cultivos celulares infectados con micoplasma.
YU295A (sh) Postupci za sprečavanje degradacije proteina c
ATE59894T1 (de) Verfahren zur indirekten beleuchtung von innenraeumen im allgemeinen, insbesondere von sogenannten offenen arbeitsraeumen und system zur indirekten beleuchtung gemaess diesem verfahren.
WO1996005286A3 (en) Cell death accelerator and cell death inhibitor
ATE148105T1 (de) Succinoylaminohydroxyäthylaminosulfamidsäureder vate und ihre verwendung als retrovirale proteasehemmer
PT561141E (pt) Solucao altamente concentrada em aminoacidos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 591605

Country of ref document: ES